<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two clinical trials were undertaken to evaluate the effect of human recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) in pancytopenic pediatric patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and Fanconi's <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In the <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> trial, 9 out of 12 patients had some improvement when treated with GM-CSF </plain></SENT>
<SENT sid="2" pm="."><plain>In the Fanconi's <z:hpo ids='HP_0001903'>anemia</z:hpo> trial, 6 of 7 patients showed some improvement when treated with GM-CSF </plain></SENT>
<SENT sid="3" pm="."><plain>For both groups, improvement in white blood cell count and absolute neutrophil count were the most common response </plain></SENT>
<SENT sid="4" pm="."><plain>Side effects observed during these studies were <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e>, <z:hpo ids='HP_0001025'>urticaria</z:hpo>, and flu-like symptoms </plain></SENT>
<SENT sid="5" pm="."><plain>Nursing care of both groups focused on the effects of <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, as well as the potential adverse effects of GM-CSF </plain></SENT>
<SENT sid="6" pm="."><plain>Patient education focused on teaching drug preparation and storage, subcutaneous injection, and potential side effects </plain></SENT>
</text></document>